Pharmaceutical manufacturer Granules India (NSE:GRANULES, BOM:532482), has received an establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for its Unit V facility at Jawaharlal Nehru Pharma City in Andhra Pradesh, India, according to a Friday filing to the stock exchanges.
The EIR follows an inspection conducted by the US FDA from April 8 to April 12 which classified the facility as a 'No Action Indicated' (NAI) indicating that no further regulatory action is required.
The regulator had conducted a comprehensive Pre-Approval Inspection (PAI) and current Good Manufacturing Practices (cGMP) audit, which concluded with zero Form 483 observations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。